Aditxt Revenue

In the year 2024, Aditxt had annual revenue of $133.99K, down -79.23%. Aditxt had revenue of $3.18K in the quarter ending December 31, 2024, a decrease of -96.09%.

Revenue (ttm)

$133.99K

Revenue Growth

-79.23%

P/S Ratio

0.23

Revenue / Employee

$5,153

Employees

Market Cap

2.67M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	133.99K	-511.19K	-79.23%
Dec 31, 2023	645.18K	-288.54K	-30.90%
Dec 31, 2022	933.72K	828.68K	788.96%
Dec 31, 2021	105.03K	-	-
Dec 31, 2020	-	-	-
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
UnitedHealth Group	410.06B
Johnson & Johnson	89.33B
Merck & Co.	63.92B
AbbVie	56.33B
AstraZeneca	54.07B
Novartis AG	51.72B
Eli Lilly and Company	45.04B
Thermo Fisher Scientific	42.90B

Revenue Rankings

ADTX News

10 days ago - Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™ - Business Wire
11 days ago - Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 - Business Wire
13 days ago - Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials - Business Wire
16 days ago - Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements - Business Wire
18 days ago - Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements - Business Wire
25 days ago - Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025 - Business Wire
4 weeks ago - Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection - Business Wire
4 weeks ago - Evofem Reports Fourth Consecutive Year of Net Sales Growth - PRNewsWire

More News